Welcome to our dedicated page for Design Therapeutics SEC filings (Ticker: DSGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Design Therapeutics, Inc. filings document the regulatory disclosures of a Nasdaq-listed, clinical-stage biotechnology company developing GeneTAC® small-molecule therapies for serious degenerative genetic diseases. Its 8-K reports furnish financial results, corporate presentations, pipeline updates, and material governance events tied to board appointments, resignations, committee assignments, director compensation, and indemnification arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, stockholder voting procedures, and board structure. The filing record also identifies the company’s common stock registration on The Nasdaq Global Select Market, emerging growth company status, and public-company disclosure framework for operations, capital structure, governance, and risk reporting.
Design Therapeutics reported a Form 144 notice proposing the sale of 217,627 common shares, with an aggregate market value of $1,083,783.00, scheduled approximately for 08/13/2025 on NASDAQ through broker BTIG, LLC. The filing shows the shares were originally acquired on 01/25/2021 in a private market transaction from Design Therapeutics, with 1,984,733 shares acquired and paid in cash on that date. The filer reports no securities sold in the past three months and affirms they are unaware of any undisclosed material adverse information about the issuer.
Design Therapeutics filed a Form 144 reporting a proposed sale of 345,000 common shares through BTIG, LLC with an aggregate market value of $1,718,100.00. The filing lists 56,900,000 shares outstanding and shows the shares were acquired on 03/26/2021 in the open market (700,000 acquired) with cash payment.
The Form 144 indicates an approximate sale date of 08/13/2025, notes nothing to report for securities sold in the past three months, and includes the filers representation that they are not aware of any undisclosed material adverse information about the issuer.